Arlinda Lee


Canaccord Boosts Price Target on Summit Therapeutics PLC (ADR) (SMMT) Following Collaboration Agreement with Sarepta Therapeutics Inc (SRPT)

Yesterday, Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a collaboration and license agreement, which will grant Sarepta Therapeutics Inc (NASDAQ:SRPT) European Union commercialization rights …

Canaccord Reiterates Buy on Ultragenyx Pharmaceutical Inc (RARE) Following Positive Phase 3 Trial

In a research report issued Friday, Canaccord analyst Arlinda Lee reiterated a Buy rating on shares of Ultragenyx Pharmaceutical Inc (NASDA:RARE) with a price …

MLV Cuts Price Target For Karyopharm Therapeutics Inc Due To Increased Risk In AML Program

In a research report released today, MLV analyst Arlinda Lee maintained a Buy rating on shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI), and reduced the …

MLV Reiterates Buy On Synta Pharmaceuticals Corp. Following 2Q:15 Results

MLV analyst Arlinda Lee weighed in with a few insights on Synta Pharmaceuticals Corp. (NASDAQ:SNTA), after the company released its second-quarter results and provided update on its pipeline.

Keryx Biopharmaceuticals (KERX)’s Auryxia Added to Two Medical Formularies; Analysts Weigh In

On Wednesday, Keryx Biopharmaceuticals (NASDAQ:KERX) made the announcement that two major insurance providers added Auryxia, a drug used to control serum phosphorous levels in patients with …

MLV Reiterates Buy on Halozyme Therapeutics, Inc. Following License Agreement With AbbVie Inc

In a research note issued today, MLV analyst Arlinda Lee reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) with a price target of $20, following the …

MLV Shines Light on Halozyme Therapeutics, Inc. (HALO) Interim Phase 2 PEGPH20 Restults

MLV’s healthcare analyst Arlinda Lee weighed in today with his views on Halozyme Therapeutics, Inc. (NASDAQ:HALO), after the company announced interim findings from the ongoing phase …

Lpath, Inc. (LPTN) Bullish Stance Reiterated at MLV

Lpath, Inc. (NASDAQ:LPTN) has been reiterated as a Buy at MLV by research analyst Arlinda Lee.

MLV Reiterates Buy on pSivida Corp. as Medidur Phase 3 Enrollment Completed

MLV’s healthcare analyst Arlinda Lee weighed in with her views on pSivida Corp. (NASDAQ:PSDV) following the news that the company has completed enrollment in the Phase 3 …

MLV Pounds the Table on Agenus Inc

MLV analyst Arlinda Lee was out pounding the table on Agenus Inc (NASDAQ:AGEN) Wednesday, reiterating a Buy rating and price target of $9.00, which implies an upside of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts